A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participants
RAP-219-103
Phase 1 other active
Quick answer
A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participants for Epilepsy is a Phase 1 program (other) at Rapport Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rapport Therapeutics
- Indication
- Epilepsy
- Phase
- Phase 1
- Modality
- other
- Status
- active